Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Thousands |
3 Months Ended |
12 Months Ended |
Mar. 31, 2017 |
Dec. 31, 2016 |
Sep. 30, 2016 |
Jun. 30, 2016 |
Mar. 31, 2016 |
Dec. 31, 2015 |
Sep. 30, 2015 |
Jun. 30, 2015 |
Mar. 31, 2017 |
Mar. 31, 2016 |
Mar. 31, 2015 |
Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
$ 11,090
|
$ 31,641
|
$ 32,195
|
$ (5,531)
|
$ 13,936
|
$ 27,995
|
$ 31,803
|
$ 26,173
|
$ 69,395
|
$ 99,907
|
$ 78,260
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
25,792
|
23,676
|
17,740
|
Loss on divestitures and sales of property and equipment |
268
|
$ (3,405)
|
$ (496)
|
55,453
|
|
|
|
|
51,820
|
0
|
0
|
Gain on sale of asset |
|
|
|
|
|
|
|
|
0
|
0
|
(1,133)
|
Deferred income taxes |
|
|
|
|
|
|
|
|
(5,778)
|
46,152
|
28,922
|
Long term income taxes payable |
|
|
|
|
|
|
|
|
581
|
(332)
|
2,294
|
Amortization of debt origination costs |
|
|
|
|
|
|
|
|
8,633
|
8,994
|
8,821
|
Stock-based compensation costs |
|
|
|
|
|
|
|
|
8,148
|
9,954
|
6,918
|
Loss on extinguishment of debt |
|
|
|
|
|
|
|
|
1,420
|
17,970
|
0
|
Lease termination costs |
|
|
|
|
|
|
|
|
524
|
0
|
785
|
Premium payment on 2012 Senior Notes |
|
|
|
|
|
|
|
|
0
|
(10,158)
|
0
|
Loss (gain) on sale or disposal of property and equipment |
|
|
|
|
|
|
|
|
573
|
(35)
|
321
|
Equity in (income) loss of subsidiaries |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Changes in operating assets and liabilities, net of effects from acquisitions: |
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
|
|
|
|
(18,938)
|
1,824
|
1,608
|
Inventories |
|
|
|
|
|
|
|
|
(10,262)
|
(3,005)
|
15,360
|
Prepaid expenses and other assets |
|
|
|
|
|
|
|
|
(1,996)
|
(7,921)
|
4,664
|
Accounts payable |
|
|
|
|
|
|
|
|
21,447
|
(11,348)
|
(17,637)
|
Accrued liabilities |
|
|
|
|
|
|
|
|
2,497
|
(1,328)
|
9,332
|
Noncurrent assets and liabilities |
|
|
|
|
|
|
|
|
(6,084)
|
0
|
0
|
Net cash provided by operating activities |
|
|
|
|
|
|
|
|
147,772
|
174,350
|
156,255
|
Investing Activities |
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
|
|
|
|
|
|
(2,977)
|
(3,568)
|
(6,101)
|
Proceeds from divestitures |
|
|
|
|
|
|
|
|
110,717
|
0
|
18,500
|
Proceeds from the sale of property and equipment |
|
|
|
|
|
|
|
|
85
|
344
|
0
|
Proceeds from sale of asset |
|
|
|
|
|
|
|
|
0
|
0
|
10,000
|
Proceeds from Insight Pharmaceuticals working capital arbitration settlement |
|
|
|
|
|
|
|
|
0
|
7,237
|
0
|
Proceeds from DenTek working capital arbitration settlement |
|
|
|
|
|
|
|
|
1,419
|
0
|
0
|
Acquisition of DenTek, less cash acquired |
|
|
|
|
|
|
|
|
0
|
(226,984)
|
0
|
Acquisition of Insight Pharmaceuticals, less cash acquired |
|
|
|
|
|
|
|
|
0
|
0
|
(749,666)
|
Acquisition of the Hydralyte brand |
|
|
|
|
|
|
|
|
0
|
0
|
(77,991)
|
Acquisition of C.B. Fleet, less cash acquired |
|
|
|
|
|
|
|
|
(803,839)
|
0
|
0
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Net cash used in investing activities |
|
|
|
|
|
|
|
|
(694,595)
|
(222,971)
|
(805,258)
|
Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of Term Loan |
|
|
|
|
|
|
|
|
1,427,000
|
0
|
720,000
|
Term Loan repayments resulting from refinancing |
|
|
|
|
|
|
|
|
(687,000)
|
0
|
0
|
Proceeds from issuance of 2016 Senior Notes |
|
|
|
|
|
|
|
|
0
|
350,000
|
0
|
Repayment of 2012 Senior Notes |
|
|
|
|
|
|
|
|
0
|
(250,000)
|
0
|
Borrowings under Bridge term loans |
|
|
|
|
|
|
|
|
0
|
80,000
|
0
|
Repayments under Bridge term loans |
|
|
|
|
|
|
|
|
0
|
(80,000)
|
0
|
Term Loan repayments |
|
|
|
|
|
|
|
|
(175,500)
|
(60,000)
|
(130,000)
|
Borrowings under revolving credit agreement |
|
|
|
|
|
|
|
|
110,000
|
115,000
|
124,600
|
Repayments under revolving credit agreement |
|
|
|
|
|
|
|
|
(105,000)
|
(96,100)
|
(58,500)
|
Payments of debt origination costs |
|
|
|
|
|
|
|
|
(11,140)
|
(11,828)
|
(16,072)
|
Proceeds from exercise of stock options |
|
|
|
|
|
|
|
|
4,028
|
6,689
|
3,954
|
Proceeds from restricted stock exercises |
|
|
|
|
|
|
|
|
0
|
544
|
57
|
Excess tax benefits from share-based awards |
|
|
|
|
|
|
|
|
900
|
1,960
|
1,330
|
Fair value of shares surrendered as payment of tax withholding |
|
|
|
|
|
|
|
|
(1,431)
|
(2,229)
|
(2,104)
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Net cash provided by financing activities |
|
|
|
|
|
|
|
|
561,857
|
54,036
|
643,265
|
Effects of exchange rate changes on cash and cash equivalents |
|
|
|
|
|
|
|
|
(409)
|
497
|
(1,275)
|
Increase (decrease) in cash and cash equivalents |
|
|
|
|
|
|
|
|
14,625
|
5,912
|
(7,013)
|
Cash and cash equivalents - beginning of year |
|
|
|
27,230
|
|
|
|
21,318
|
27,230
|
21,318
|
28,331
|
Cash and cash equivalents - end of year |
41,855
|
|
|
|
27,230
|
|
|
|
41,855
|
27,230
|
21,318
|
Prestige Brands Holdings, Inc. |
|
|
|
|
|
|
|
|
|
|
|
Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
|
|
69,395
|
99,907
|
78,260
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
3,170
|
4,050
|
3,381
|
Loss on divestitures and sales of property and equipment |
|
|
|
|
|
|
|
|
0
|
|
|
Gain on sale of asset |
|
|
|
|
|
|
|
|
|
|
0
|
Deferred income taxes |
|
|
|
|
|
|
|
|
316
|
136
|
(192)
|
Long term income taxes payable |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Amortization of debt origination costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Stock-based compensation costs |
|
|
|
|
|
|
|
|
8,148
|
9,794
|
6,918
|
Loss on extinguishment of debt |
|
|
|
|
|
|
|
|
0
|
0
|
|
Lease termination costs |
|
|
|
|
|
|
|
|
0
|
|
0
|
Premium payment on 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Loss (gain) on sale or disposal of property and equipment |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Equity in (income) loss of subsidiaries |
|
|
|
|
|
|
|
|
(67,467)
|
(98,803)
|
(76,383)
|
Changes in operating assets and liabilities, net of effects from acquisitions: |
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
|
|
|
|
0
|
0
|
473
|
Inventories |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Prepaid expenses and other assets |
|
|
|
|
|
|
|
|
(2,261)
|
(9,580)
|
2,273
|
Accounts payable |
|
|
|
|
|
|
|
|
(790)
|
929
|
(2,457)
|
Accrued liabilities |
|
|
|
|
|
|
|
|
620
|
1,907
|
2,650
|
Net cash provided by operating activities |
|
|
|
|
|
|
|
|
11,131
|
8,340
|
14,923
|
Investing Activities |
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
|
|
|
|
|
|
(1,153)
|
(2,460)
|
(5,029)
|
Proceeds from divestitures |
|
|
|
|
|
|
|
|
0
|
|
0
|
Proceeds from the sale of property and equipment |
|
|
|
|
|
|
|
|
0
|
0
|
|
Proceeds from sale of asset |
|
|
|
|
|
|
|
|
|
|
0
|
Proceeds from Insight Pharmaceuticals working capital arbitration settlement |
|
|
|
|
|
|
|
|
|
0
|
|
Proceeds from DenTek working capital arbitration settlement |
|
|
|
|
|
|
|
|
0
|
|
|
Acquisition of DenTek, less cash acquired |
|
|
|
|
|
|
|
|
|
0
|
|
Acquisition of Insight Pharmaceuticals, less cash acquired |
|
|
|
|
|
|
|
|
|
|
0
|
Acquisition of the Hydralyte brand |
|
|
|
|
|
|
|
|
|
|
0
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Net cash used in investing activities |
|
|
|
|
|
|
|
|
(1,153)
|
(2,460)
|
(5,029)
|
Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of Term Loan |
|
|
|
|
|
|
|
|
0
|
|
0
|
Term Loan repayments resulting from refinancing |
|
|
|
|
|
|
|
|
0
|
|
|
Proceeds from issuance of 2016 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Repayment of 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Borrowings under Bridge term loans |
|
|
|
|
|
|
|
|
|
0
|
|
Repayments under Bridge term loans |
|
|
|
|
|
|
|
|
|
0
|
|
Term Loan repayments |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Borrowings under revolving credit agreement |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Repayments under revolving credit agreement |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Payments of debt origination costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Proceeds from exercise of stock options |
|
|
|
|
|
|
|
|
4,028
|
6,689
|
3,954
|
Proceeds from restricted stock exercises |
|
|
|
|
|
|
|
|
|
544
|
57
|
Excess tax benefits from share-based awards |
|
|
|
|
|
|
|
|
900
|
1,960
|
1,330
|
Fair value of shares surrendered as payment of tax withholding |
|
|
|
|
|
|
|
|
(1,431)
|
(2,229)
|
(2,104)
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
(11,747)
|
(19,791)
|
(26,388)
|
Net cash provided by financing activities |
|
|
|
|
|
|
|
|
(8,250)
|
(12,827)
|
(23,151)
|
Effects of exchange rate changes on cash and cash equivalents |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Increase (decrease) in cash and cash equivalents |
|
|
|
|
|
|
|
|
1,728
|
(6,947)
|
(13,257)
|
Cash and cash equivalents - beginning of year |
|
|
|
4,440
|
|
|
|
11,387
|
4,440
|
11,387
|
24,644
|
Cash and cash equivalents - end of year |
6,168
|
|
|
|
4,440
|
|
|
|
6,168
|
4,440
|
11,387
|
Prestige Brands, Inc., the issuer |
|
|
|
|
|
|
|
|
|
|
|
Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
|
|
68,463
|
90,201
|
77,881
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
634
|
594
|
592
|
Loss on divestitures and sales of property and equipment |
|
|
|
|
|
|
|
|
0
|
|
|
Gain on sale of asset |
|
|
|
|
|
|
|
|
|
|
0
|
Deferred income taxes |
|
|
|
|
|
|
|
|
(3,691)
|
1,272
|
2,462
|
Long term income taxes payable |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Amortization of debt origination costs |
|
|
|
|
|
|
|
|
8,633
|
8,994
|
8,821
|
Stock-based compensation costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Loss on extinguishment of debt |
|
|
|
|
|
|
|
|
1,420
|
17,970
|
|
Lease termination costs |
|
|
|
|
|
|
|
|
0
|
|
0
|
Premium payment on 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
(10,158)
|
|
Loss (gain) on sale or disposal of property and equipment |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Equity in (income) loss of subsidiaries |
|
|
|
|
|
|
|
|
(49,302)
|
(70,953)
|
(51,573)
|
Changes in operating assets and liabilities, net of effects from acquisitions: |
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
|
|
|
|
(3,762)
|
2,514
|
(294)
|
Inventories |
|
|
|
|
|
|
|
|
(7,073)
|
(744)
|
5,690
|
Prepaid expenses and other assets |
|
|
|
|
|
|
|
|
(1,428)
|
(116)
|
(28)
|
Accounts payable |
|
|
|
|
|
|
|
|
6,933
|
814
|
(829)
|
Accrued liabilities |
|
|
|
|
|
|
|
|
184
|
(2,749)
|
1,384
|
Net cash provided by operating activities |
|
|
|
|
|
|
|
|
21,011
|
37,639
|
44,106
|
Investing Activities |
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
|
|
|
|
|
|
(327)
|
(93)
|
(119)
|
Proceeds from divestitures |
|
|
|
|
|
|
|
|
0
|
|
0
|
Proceeds from the sale of property and equipment |
|
|
|
|
|
|
|
|
0
|
0
|
|
Proceeds from sale of asset |
|
|
|
|
|
|
|
|
|
|
0
|
Proceeds from Insight Pharmaceuticals working capital arbitration settlement |
|
|
|
|
|
|
|
|
|
0
|
|
Proceeds from DenTek working capital arbitration settlement |
|
|
|
|
|
|
|
|
0
|
|
|
Acquisition of DenTek, less cash acquired |
|
|
|
|
|
|
|
|
|
0
|
|
Acquisition of Insight Pharmaceuticals, less cash acquired |
|
|
|
|
|
|
|
|
|
|
0
|
Acquisition of the Hydralyte brand |
|
|
|
|
|
|
|
|
|
|
0
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
(823,723)
|
(228,343)
|
(809,157)
|
Net cash used in investing activities |
|
|
|
|
|
|
|
|
(824,050)
|
(228,436)
|
(809,276)
|
Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of Term Loan |
|
|
|
|
|
|
|
|
1,427,000
|
|
720,000
|
Term Loan repayments resulting from refinancing |
|
|
|
|
|
|
|
|
(687,000)
|
|
|
Proceeds from issuance of 2016 Senior Notes |
|
|
|
|
|
|
|
|
|
350,000
|
|
Repayment of 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
(250,000)
|
|
Borrowings under Bridge term loans |
|
|
|
|
|
|
|
|
|
80,000
|
|
Repayments under Bridge term loans |
|
|
|
|
|
|
|
|
|
(80,000)
|
|
Term Loan repayments |
|
|
|
|
|
|
|
|
(175,500)
|
(60,000)
|
(130,000)
|
Borrowings under revolving credit agreement |
|
|
|
|
|
|
|
|
110,000
|
115,000
|
124,600
|
Repayments under revolving credit agreement |
|
|
|
|
|
|
|
|
(105,000)
|
(96,100)
|
(58,500)
|
Payments of debt origination costs |
|
|
|
|
|
|
|
|
(11,140)
|
(11,828)
|
(16,072)
|
Proceeds from exercise of stock options |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Proceeds from restricted stock exercises |
|
|
|
|
|
|
|
|
|
0
|
0
|
Excess tax benefits from share-based awards |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Fair value of shares surrendered as payment of tax withholding |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
244,679
|
143,725
|
125,142
|
Net cash provided by financing activities |
|
|
|
|
|
|
|
|
803,039
|
190,797
|
765,170
|
Effects of exchange rate changes on cash and cash equivalents |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Increase (decrease) in cash and cash equivalents |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Cash and cash equivalents - beginning of year |
|
|
|
0
|
|
|
|
0
|
0
|
0
|
0
|
Cash and cash equivalents - end of year |
0
|
|
|
|
0
|
|
|
|
0
|
0
|
0
|
Combined Subsidiary Guarantors |
|
|
|
|
|
|
|
|
|
|
|
Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
|
|
48,737
|
78,941
|
50,209
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
21,454
|
18,617
|
12,752
|
Loss on divestitures and sales of property and equipment |
|
|
|
|
|
|
|
|
51,820
|
|
|
Gain on sale of asset |
|
|
|
|
|
|
|
|
|
|
(1,133)
|
Deferred income taxes |
|
|
|
|
|
|
|
|
(1,934)
|
45,070
|
26,795
|
Long term income taxes payable |
|
|
|
|
|
|
|
|
581
|
(332)
|
2,294
|
Amortization of debt origination costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Stock-based compensation costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Loss on extinguishment of debt |
|
|
|
|
|
|
|
|
0
|
0
|
|
Lease termination costs |
|
|
|
|
|
|
|
|
524
|
|
785
|
Premium payment on 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Loss (gain) on sale or disposal of property and equipment |
|
|
|
|
|
|
|
|
573
|
1
|
0
|
Equity in (income) loss of subsidiaries |
|
|
|
|
|
|
|
|
(9,481)
|
(8,564)
|
(2,013)
|
Changes in operating assets and liabilities, net of effects from acquisitions: |
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
|
|
|
|
(5,725)
|
(388)
|
5,146
|
Inventories |
|
|
|
|
|
|
|
|
(2,856)
|
213
|
8,981
|
Prepaid expenses and other assets |
|
|
|
|
|
|
|
|
1,235
|
1,977
|
2,631
|
Accounts payable |
|
|
|
|
|
|
|
|
14,155
|
(11,284)
|
(16,734)
|
Accrued liabilities |
|
|
|
|
|
|
|
|
1,798
|
(1,943)
|
3,560
|
Noncurrent assets and liabilities |
|
|
|
|
|
|
|
|
(6,084)
|
|
|
Net cash provided by operating activities |
|
|
|
|
|
|
|
|
114,797
|
122,308
|
93,273
|
Investing Activities |
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
|
|
|
|
|
|
(1,378)
|
(521)
|
(739)
|
Proceeds from divestitures |
|
|
|
|
|
|
|
|
110,717
|
|
18,500
|
Proceeds from the sale of property and equipment |
|
|
|
|
|
|
|
|
85
|
0
|
|
Proceeds from sale of asset |
|
|
|
|
|
|
|
|
|
|
10,000
|
Proceeds from Insight Pharmaceuticals working capital arbitration settlement |
|
|
|
|
|
|
|
|
|
7,237
|
|
Proceeds from DenTek working capital arbitration settlement |
|
|
|
|
|
|
|
|
1,419
|
|
|
Acquisition of DenTek, less cash acquired |
|
|
|
|
|
|
|
|
|
(226,984)
|
|
Acquisition of Insight Pharmaceuticals, less cash acquired |
|
|
|
|
|
|
|
|
|
|
(749,666)
|
Acquisition of the Hydralyte brand |
|
|
|
|
|
|
|
|
|
|
0
|
Acquisition of C.B. Fleet, less cash acquired |
|
|
|
|
|
|
|
|
(803,839)
|
|
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
823,723
|
228,343
|
731,166
|
Net cash used in investing activities |
|
|
|
|
|
|
|
|
130,727
|
8,075
|
9,261
|
Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of Term Loan |
|
|
|
|
|
|
|
|
0
|
|
0
|
Term Loan repayments resulting from refinancing |
|
|
|
|
|
|
|
|
0
|
|
|
Proceeds from issuance of 2016 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Repayment of 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Borrowings under Bridge term loans |
|
|
|
|
|
|
|
|
|
0
|
|
Repayments under Bridge term loans |
|
|
|
|
|
|
|
|
|
0
|
|
Term Loan repayments |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Borrowings under revolving credit agreement |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Repayments under revolving credit agreement |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Payments of debt origination costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Proceeds from exercise of stock options |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Proceeds from restricted stock exercises |
|
|
|
|
|
|
|
|
|
0
|
0
|
Excess tax benefits from share-based awards |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Fair value of shares surrendered as payment of tax withholding |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
(243,439)
|
(127,484)
|
(102,534)
|
Net cash provided by financing activities |
|
|
|
|
|
|
|
|
(243,439)
|
(127,484)
|
(102,534)
|
Effects of exchange rate changes on cash and cash equivalents |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Increase (decrease) in cash and cash equivalents |
|
|
|
|
|
|
|
|
2,085
|
2,899
|
0
|
Cash and cash equivalents - beginning of year |
|
|
|
2,899
|
|
|
|
0
|
2,899
|
0
|
0
|
Cash and cash equivalents - end of year |
4,984
|
|
|
|
2,899
|
|
|
|
4,984
|
2,899
|
0
|
Combined Non-Guarantor Subsidiaries |
|
|
|
|
|
|
|
|
|
|
|
Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
|
|
9,481
|
8,564
|
2,013
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
534
|
415
|
1,015
|
Loss on divestitures and sales of property and equipment |
|
|
|
|
|
|
|
|
0
|
|
|
Gain on sale of asset |
|
|
|
|
|
|
|
|
|
|
0
|
Deferred income taxes |
|
|
|
|
|
|
|
|
(469)
|
(326)
|
(143)
|
Long term income taxes payable |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Amortization of debt origination costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Stock-based compensation costs |
|
|
|
|
|
|
|
|
|
160
|
0
|
Loss on extinguishment of debt |
|
|
|
|
|
|
|
|
0
|
0
|
|
Lease termination costs |
|
|
|
|
|
|
|
|
0
|
|
0
|
Premium payment on 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Loss (gain) on sale or disposal of property and equipment |
|
|
|
|
|
|
|
|
0
|
(36)
|
321
|
Equity in (income) loss of subsidiaries |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Changes in operating assets and liabilities, net of effects from acquisitions: |
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
|
|
|
|
(9,451)
|
(302)
|
(3,717)
|
Inventories |
|
|
|
|
|
|
|
|
(764)
|
(1,860)
|
555
|
Prepaid expenses and other assets |
|
|
|
|
|
|
|
|
458
|
(202)
|
(212)
|
Accounts payable |
|
|
|
|
|
|
|
|
1,149
|
(1,807)
|
2,383
|
Accrued liabilities |
|
|
|
|
|
|
|
|
(105)
|
1,457
|
1,738
|
Net cash provided by operating activities |
|
|
|
|
|
|
|
|
833
|
6,063
|
3,953
|
Investing Activities |
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
|
|
|
|
|
|
(119)
|
(494)
|
(214)
|
Proceeds from divestitures |
|
|
|
|
|
|
|
|
0
|
|
0
|
Proceeds from the sale of property and equipment |
|
|
|
|
|
|
|
|
|
344
|
|
Proceeds from sale of asset |
|
|
|
|
|
|
|
|
|
|
0
|
Proceeds from Insight Pharmaceuticals working capital arbitration settlement |
|
|
|
|
|
|
|
|
|
0
|
|
Proceeds from DenTek working capital arbitration settlement |
|
|
|
|
|
|
|
|
0
|
|
|
Acquisition of DenTek, less cash acquired |
|
|
|
|
|
|
|
|
|
0
|
|
Acquisition of Insight Pharmaceuticals, less cash acquired |
|
|
|
|
|
|
|
|
|
|
0
|
Acquisition of the Hydralyte brand |
|
|
|
|
|
|
|
|
|
|
(77,991)
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
0
|
0
|
77,991
|
Net cash used in investing activities |
|
|
|
|
|
|
|
|
(119)
|
(150)
|
(214)
|
Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of Term Loan |
|
|
|
|
|
|
|
|
0
|
|
0
|
Term Loan repayments resulting from refinancing |
|
|
|
|
|
|
|
|
0
|
|
|
Proceeds from issuance of 2016 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Repayment of 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Borrowings under Bridge term loans |
|
|
|
|
|
|
|
|
|
0
|
|
Repayments under Bridge term loans |
|
|
|
|
|
|
|
|
|
0
|
|
Term Loan repayments |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Borrowings under revolving credit agreement |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Repayments under revolving credit agreement |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Payments of debt origination costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Proceeds from exercise of stock options |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Proceeds from restricted stock exercises |
|
|
|
|
|
|
|
|
|
0
|
0
|
Excess tax benefits from share-based awards |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Fair value of shares surrendered as payment of tax withholding |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
10,507
|
3,550
|
3,780
|
Net cash provided by financing activities |
|
|
|
|
|
|
|
|
10,507
|
3,550
|
3,780
|
Effects of exchange rate changes on cash and cash equivalents |
|
|
|
|
|
|
|
|
(409)
|
497
|
(1,275)
|
Increase (decrease) in cash and cash equivalents |
|
|
|
|
|
|
|
|
10,812
|
9,960
|
6,244
|
Cash and cash equivalents - beginning of year |
|
|
|
19,891
|
|
|
|
9,931
|
19,891
|
9,931
|
3,687
|
Cash and cash equivalents - end of year |
30,703
|
|
|
|
19,891
|
|
|
|
30,703
|
19,891
|
9,931
|
Eliminations |
|
|
|
|
|
|
|
|
|
|
|
Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
|
|
(126,681)
|
(177,706)
|
(130,103)
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Loss on divestitures and sales of property and equipment |
|
|
|
|
|
|
|
|
0
|
|
|
Gain on sale of asset |
|
|
|
|
|
|
|
|
|
|
0
|
Deferred income taxes |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Long term income taxes payable |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Amortization of debt origination costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Stock-based compensation costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Loss on extinguishment of debt |
|
|
|
|
|
|
|
|
0
|
0
|
|
Lease termination costs |
|
|
|
|
|
|
|
|
0
|
|
0
|
Premium payment on 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Loss (gain) on sale or disposal of property and equipment |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Equity in (income) loss of subsidiaries |
|
|
|
|
|
|
|
|
126,250
|
178,320
|
129,969
|
Changes in operating assets and liabilities, net of effects from acquisitions: |
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Inventories |
|
|
|
|
|
|
|
|
431
|
(614)
|
134
|
Prepaid expenses and other assets |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Accounts payable |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Accrued liabilities |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Net cash provided by operating activities |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Investing Activities |
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Proceeds from divestitures |
|
|
|
|
|
|
|
|
0
|
|
0
|
Proceeds from the sale of property and equipment |
|
|
|
|
|
|
|
|
0
|
0
|
|
Proceeds from sale of asset |
|
|
|
|
|
|
|
|
|
|
0
|
Proceeds from Insight Pharmaceuticals working capital arbitration settlement |
|
|
|
|
|
|
|
|
|
0
|
|
Proceeds from DenTek working capital arbitration settlement |
|
|
|
|
|
|
|
|
0
|
|
|
Acquisition of DenTek, less cash acquired |
|
|
|
|
|
|
|
|
|
0
|
|
Acquisition of Insight Pharmaceuticals, less cash acquired |
|
|
|
|
|
|
|
|
|
|
0
|
Acquisition of the Hydralyte brand |
|
|
|
|
|
|
|
|
|
|
0
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Net cash used in investing activities |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of Term Loan |
|
|
|
|
|
|
|
|
0
|
|
0
|
Term Loan repayments resulting from refinancing |
|
|
|
|
|
|
|
|
0
|
|
|
Proceeds from issuance of 2016 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Repayment of 2012 Senior Notes |
|
|
|
|
|
|
|
|
|
0
|
|
Borrowings under Bridge term loans |
|
|
|
|
|
|
|
|
|
0
|
|
Repayments under Bridge term loans |
|
|
|
|
|
|
|
|
|
0
|
|
Term Loan repayments |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Borrowings under revolving credit agreement |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Repayments under revolving credit agreement |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Payments of debt origination costs |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Proceeds from exercise of stock options |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Proceeds from restricted stock exercises |
|
|
|
|
|
|
|
|
|
0
|
0
|
Excess tax benefits from share-based awards |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Fair value of shares surrendered as payment of tax withholding |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Intercompany activity, net |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Net cash provided by financing activities |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Effects of exchange rate changes on cash and cash equivalents |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Increase (decrease) in cash and cash equivalents |
|
|
|
|
|
|
|
|
0
|
0
|
0
|
Cash and cash equivalents - beginning of year |
|
|
|
$ 0
|
|
|
|
$ 0
|
0
|
0
|
0
|
Cash and cash equivalents - end of year |
$ 0
|
|
|
|
$ 0
|
|
|
|
$ 0
|
$ 0
|
$ 0
|